Objective: Oral P2Y 12 platelet receptor inhibitors are a cornerstone of reducing complications in patients with acute coronary syndromes or coronary stents. Guidelines advocate discontinuing treatment with P2Y 12 platelet receptor inhibitors before surgery. Cangrelor, a short-acting, reversible, intravenously administered P2Y 12 platelet inhibitor is effective in achieving appropriate platelet inhibition in patients who are awaiting coronary artery bypass grafting (CABG) and require P2Y 12 inhibition. The objective of this study was to assess the effects of preoperative cangrelor on the incidence of perioperative complications, which are currently unknown.
IntroductIon
The use of dual antiplatelet therapy, specifically the combination of aspirin and an oral P2Y 12 receptor inhibitor such as clopidogrel, prasugrel, or ticagrelor, is the standard of care for patients who present with acute coronary syndromes (ACS) or who have recently placed coronary stents [Lewis 2005; Chen 2005; Sabatine 2005] . Early platelet inhibition with P2Y12 platelet receptor has been shown to reduce the risk of recurrent ischemic events inhibitors in these patients. Several large studies of patients presenting with ACS have shown, however, that 10% to 15% of patients require surgical intervention [Yusuf 2001 ]. Continuation of P2Y 12 inhibition up until the time of surgery reduces the risk of preoperative ischemic events, but it may also increase the risks of bleeding and bleeding-related complications. Although current guidelines recommend withholding thienopyridine therapy for at least 5 to 7 days for clopidogrel, 5 days for ticagrelor, and 7 days for prasugrel before planned coronary artery bypass grafting surgery (CABG), adherence to these guidelines still exposes patients to an increased risk of preoperative ischemic events [Wright 2011] . Although the risk is poorly defined, some investigators have suggested a 10% to 15% risk of major adverse events during the "washout" period in patients in whom thienopyridines are held prior to surgery [Sambu 2011] . Evidence also suggests that a "rebound" phenomenon with increased platelet reactivity could occur with an abrupt withdrawal, which might also predispose the patient to recurrent ischemic events [Collet 2004 ]. Optimal strategies are lacking for transitioning patients who are receiving platelet inhibition therapies and then require surgery.
Cangrelor is an intravenous, short-acting, reversible, platelet P2Y 12 inhibitor [Norgard 2009 ]. Its mechanism of action differs from oral, irreversible thienopyridines that are prodrugs and require metabolic activation and bind irreversibly to the receptor. In contrast, cangrelor directly and reversibly binds to the P2Y 12 receptor. Ticagrelor, another oral nonthienopyridine P2Y 12 inhibitor, also binds directly and reversibly. Its onset is slower (approximately 30 minutes to 1 hour, compared with immediately for cangrelor); however, the offset of effect is considerably longer (approximately 5 days) than for cangrelor. Pharmacodynamic studies have shown that platelet function returns to normal within 1 hour after cangrelor discontinuation. Our recently published report of a doubleblind, placebo-controlled trial has demonstrated that a cangrelor infusion of 0.75 μg/kg per minute provided adequate platelet inhibition in 98.8% of patients awaiting CABG. This platelet inhibition was maintained throughout the duration of therapy [Angiolillo 2012] . The objective of the present study was to assess the effects of preoperative cangrelor on the incidence of perioperative complications in the BRIDGE trial.
Methods
The design and protocol of the BRIDGE trial have already been described [Angiolillo 2012] . In brief, we conducted an open-label phase of the study to identify the cangrelor dose that produced a desired antiplatelet effect. We then identified 210 patients who had indications for thienopyridine therapy, because of either recent ACS or recent implantation of an intracoronary stent, and randomized them to an infusion of cangrelor or placebo. We used serial point-of-care testing (VerifyNow™; Accumetrics, San Diego, CA, USA) to measure platelet reactivity, which was defined as <240 platelet reaction units (PRU). Measurements were made before infusion, every day preoperatively, immediately before discontinuation of the study drug, and at the time of surgical incision. By protocol design, all patients received between 2 and 7 days of therapy with the study drug. This therapy was discontinued 1 to 6 hours before the planned CABG. All patients received aspirin during the study period. All other perioperative management decisions (ie, heparin infusions, transfusion decisions, need for reoperation, and surgical techniques) were at the discretion of the primary teams and were consistent with accepted standards of care. All events were site-reported and defined as any new complaint or diagnosis in the medical record, as reported by the treating physicians during the pre-and postoperative periods. The site-reported, protocol-defined end points of bleeding and major adverse cardiovascular/cerebrovascular end points/events (MACCE) were reported separately from other pre-and postsurgery complications (see Appendix A for definitions).
All patients provided written informed consent, and appropriate ethics committee and regulatory approval were obtained by each participating center. Study oversight was monitored by an executive committee chaired by the lead investigator (E.J.T.). The study was sponsored by The Medicines Company and was registered with ClinicialTrials.gov (http://www.clinicaltrials.gov; NCT00767507).
Statistical Analysis
The study randomized 210 patients. The safety-analysis population included the patients in the cangrelor group (n = 106) and the placebo group (n = 101) who had been randomized to receive any study drug. The patients were classified according to the actual treatment received for safety analysis. The intent-to-treat (ITT) population (cangrelor group, 93 patients; placebo group, 90 patients) was defined as all patients who were randomized to receive the study drug, except for the first 24 patients, whose data were unblinded for a planned review by the Data Safety Monitoring Board for dosing confirmation. The efficacy analysis was based on the patients in the ITT population who had valid PRU results (84 patients each in the cangrelor and placebo groups). The efficacy end point was the proportion (ie, percentage) of patients with a platelet reactivity of <240 PRU for all samples assessed during infusion of the study drug before surgery. In general, differences from baseline were compared with analysis of variance (ANOVA) for quantitative factors or with the chi-square test for proportions (or the Fisher exact test for rare events, as appropriate). The chi-square test was used to compare the differences between the 2 groups in the percentage of patients with platelet inhibition with regard to relative risk (RR) or odds ratio (OR), and their respective 95% confidence intervals (CI), which were estimated according to an approximation to normality. ANOVA was used to compare differences in PRU values. We did not apply any imputation to missing data or any α adjustment for multiple comparisons. To explore and quantify potential risk factors for bleeding, we developed a multivariate logistic model. First, we performed a univariate analysis with ANOVA or the chi-square test for each potential risk factor for bleeding. Bleeding risk was analyzed for protocol-defined excessive CABG-related bleeding and major or minor preprocedure bleeding. The ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries), or TIMI (Thrombolysis in Myocardial Infarction) bleeding scale was used (separately and in combination for the cangrelor and placebo groups; see Appendix A). Potentially significant risk factors identified in the univariate analyses with P values <.15 were then included in a multivariate logistic model to quantify the adjusted risks and to control their potential confounding effect on the effect of cangrelor treatment for bleeding.
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results
The 2 groups were similar with respect to clinical characteristics, prestudy thienopyridine use, baseline demographics, and surgical procedure performed (Table 1) . Aspirin was used in 99.1% of cangrelor-treated patients and in 96.0% of placebo patients (P = .158).
In the ITT population, values <240 PRU were observed during the entire preoperative infusion period in 98.8% (83/84) of cangrelor-treated patients and in 19.0% (16/84) of placebo patients (RR, 5.2; 95% CI, 3.3-8.1; P < .001), as previously reported. Values <240 PRU before discontinuation of the study drug prior to CABG were observed in 98.8% (83/84) of patients in the cangrelor-treated group, compared with 31.0% (26/84) of patients receiving placebo (P < .001). Immediately before surgery and after discontinuation of the study drug (1-6 hours before incision), values <240 PRU remained in 26.9% (21/78) of cangrelor-treated patients and in 20.0% (15/75) of patients receiving placebo (P = .313). The mean PRU value at the time of CABG (the median time from discontinuation of the study drug was 3.2 hours for both groups) was 279.7 PRU in the cangrelor-treated patients and 297.8 PRU in the placebo patients (P = .212). The efficacy end point (<240 PRU) was analyzed with the safety population as a sensitivity check. Results were very similar to those from the ITT analyses, thus indicating the robustness of the platelet inhibition result.
Bleeding/Transfusion
Of the randomized patients who received the study drug, 102 patients in the cangrelor group and 96 patients in the placebo group underwent surgery. There were no differences between the 2 groups with respect to excessive CABG-related bleeding (primary safety end point; see Appendix A): 11.8% Minimum, maximum, mL 150, 4300 216, 2940 *Variables are presented as the median (minimum, maximum) or as n (%). Differences were compared with analysis of variance for quantitative factors or with the chi-square test (or the Fisher exact test, as appropriate) for proportions. STEMI indicates ST-segment elevation myocardial infarction; TIA, transient ischemic attack; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous intervention; CABG, coronary artery bypass grafting surgery; CHF, congestive heart failure; LIMA, left internal mammary artery; RIMA, right internal mammary artery. †Data are presented as the mean ± SD.
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(12/102) in the cangrelor group versus 10.4% (10/96) in the placebo group (P = .763, Table 2 ). No difference was seen in bleeding according to the Bleeding Academic Research Consortium (BARC) scale (9.8% in the cangrelor group and 10.4% in the placebo group, P = .886). Major preoperative bleeding was rare in both groups. The rates of preoperative minor/mild bleeding were numerically higher in the cangrelor group than in the placebo group, but no statistically significant difference was seen on the ACUITY, GUSTO, or TIMI scale. A univariate analysis evaluated the bleeding risk for protocol-defined excessive CABG-related bleeding and preprocedure major or minor bleeding, as defined according to the ACUITY, GUSTO, and TIMI scales (in combination and separately for the cangrelor and placebo groups; see Appendix B). For excessive CABG-related bleeding, the analysis also included surgery-specific factors (Appendix C). For excessive risk of CABG-related bleeding, the univariate analysis identified the following factors as potential predictors (ie, with P values <.15): age, body mass index, history of diabetes or hyperlipidemia, previous CABG, prior treatment with unfractionated heparin or low molecular weight heparin, and CABG duration. The data were fitted into a multivariate logistic regression model, together with the treatment term. Table 3 summarizes the results of the univariate analysis and presents the adjusted OR and 95% CI values for the effects on bleeding risk. The crude OR for cangrelor on excessive CABG-related bleeding was 1.15 (95% CI, 0.47-2.79). The adjusted OR was 1.42 (95% CI, 0.49-4.07; P = .520).
Multivariate analyses of major or minor bleeding risk were performed similarly for the preoperative ACUITY, GUSTO, or TIMI scale. Table 4 summarizes the univariate effects and the multivariate logistic model effect on bleeding risk. The crude OR for the effect of cangrelor on preoperative major and minor bleeding was 1.90 (95% CI, 0.86-4.20). The adjusted OR was 2.12 (95% CI, 0.78-5.76; P = .139). We also separately evaluated the relationships between potential risk factors and preoperative major or minor bleeding for the cangrelor and placebo groups. Although the risk profile for cangrelor is similar to that of the cangrelor and placebo groups combined, the only predictive factors in the placebo group were the last thienopyridine therapy dose and the baseline PRU value. Postbaseline PRU values were analyzed in various derivations in their relationship to bleeding (excessive CABGrelated or major or minor preoperative bleeding). These values included last on-treatment PRU value, mean and median on-treatment PRU values, and posttreatment last pre-CABG PRU value. None of these PRU values were significantly related to either excessive CABG-related bleeding or preoperative major or minor bleeding.
Preoperatively, the cangrelor and placebo groups had similar blood transfusion rates: cangrelor group, 1.9% (2/106); placebo group, 1.0% (1/101) (P > .999). Similarly, in the cangrelor group 1 patient required transfusion with fresh frozen plasma, and 1 required pooled platelets. No patient in the placebo group required treatment with either plasma or platelets.
Postoperatively, the 2 groups were similar with respect to blood and blood product use. Overall, 32 of 106 patients in the cangrelor group required blood transfusion with at least 1 unit of packed red blood cells (PRBC), and 34 of 101 patients in the placebo group received at least 1 PRBC unit. The numbers of units of PRBC, platelets, and fresh frozen plasma were also similar (Table 5 ).
Thrombotic Events
The MACCE incidence was low. Preoperatively, 2.8% of cangrelor-treated patients and 4.0% of placebo-treated patients experienced an ischemic event. In the cangrelor group, 1 patient died, 2 patients experienced myocardial infarction (MI), and 1 patient had ischemic-driven revascularization (IDR). No preoperative strokes in the cangrelor group were reported; however, 3 deaths and 1 case of stroke during the preoperative period were reported in the placebo group. The incidence of these ischemic events remained low in the postoperative period, with 4 patients in each group experiencing a death, MI, IDR, or stroke from just after surgery *Data are presented as n (%) or the mean ± SD, as indicated. For univariate analyses, the chi-square test was performed for proportions, and analysis of variance was used for continuous variables. A logistic model was fitted for adjusted odds ratios (ORs) including all factors listed. CI indicates confidence interval; NA, not applicable; TIA, transient ischemic attack; CAD, coronary artery disease; PCI, percutaneous intervention; CABG, coronary artery bypass grafting surgery; UFH, unfractionated heparin; LMWH, low molecular weight heparin; PRU, platelet reaction units.
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through 30 days postoperatively. In the cangrelor group, there were 2 MI, 2 IDR, 1 stroke, and 1 death (from systemic inflammatory response syndrome), whereas the placebo group had 1 MI, 1 stroke, and 2 deaths (1 cardiogenic shock and 1 multiorgan failure). All preoperative deaths were from cardiac causes.
Other Complications
The cangrelor-treated and placebo-treated groups had similar safety profiles. The incidence of any other complications was common in patients, both preoperatively (30.2% [32/106] and 28.7% [29/101], respectively; P = .816; see Table  6 ) and postoperatively (57.8% [59/102] and 55.9% [57/96], respectively; P = .827). The rates of individual complications for the cangrelor and placebo groups were not significantly different or clinically remarkable. They tended to be minor and rarely of any clinical significance. These complications were typically nonspecific or routine occurrences for the post-CABG patient (ie, electrolyte abnormalities, edema, and so on) and were unlikely to be drug related. Table 7 lists some of the more commonly encountered postoperative complications. Still, most events were infrequent, and the 2 groups had similar rates.
Complications that met serious adverse-event criteria were uncommon preoperatively (4.7% [5/106] and 4.0% [4/101] for the cangrelor and placebo groups, respectively; P = .790) and postoperatively (7.8% [8/102] and 5.2% [5/96], respectively; P = .454).
dIscussIon
Our findings demonstrate that cangrelor was not associated with an increased risk of perioperative complications or reportable events (compared with placebo), despite preoperative platelet inhibition therapy. These findings, combined with those of our previous study, which demonstrated no increased risk of bleeding or transfusion rates [Angiolillo 2012], might have significant implications for the management of patients who are receiving thienopyridine therapy and require surgery.
Previously published trials have shown acceptable risk/ benefit profiles for patients with coronary artery disease who are undergoing a percutaneous coronary intervention (PCI). In the randomized CHAMPION PCI trial of 8877 patients, cangrelor was not superior to a 600-mg loading dose of clopidogrel when administered 30 minutes prior to a planned PCI [Harrington 2009 ]. Although major bleeding complications did not increase, cangrelor showed a significant increase in minor bleeding complications on the ACUITY scale. More importantly, there was a trend toward a decrease in biomarker-independent study end points, which included death, Q-wave MI, or IDR (cangrelor, 0.6%; clopidogrel, 0.9%; OR, 0.67; 95% CI, 0.39-1.14; P = .14). A second CHAM-PION trial (PLATFORM) randomized 5362 patients who were to undergo a PCI to either cangrelor or 600 mg clopidogrel, which was administered at the end of the PCI per the standard of care. Patients treated with cangrelor showed a slight increase in major bleeding, predominately from groin hematomas. This increased risk of bleeding did not involve an increased rate of transfusions, however, and there were decreased risks of acute stent thrombosis (cangrelor, 0.2%; placebo, 0.6%; OR, 0.31; 95% CI, 0.11-0.85; P = .02) and death (cangrelor, 0.2%; placebo, 0.7%; OR, 0.33; 95% CI, 0.13-0.83; P = .02) [Bhatt 2009 ].
Platelet inhibition is the standard of care in patients who present with ACS or have a recently implanted intracoronary stent. Continuation of thienopyridine treatment has been demonstrated to reduce the risk of recurrent ischemic events and acute coronary stent thrombosis. For the 10% to 15% of patients who present with ACS, however, current American College of Cardiology/American Heart Association (ACC/ AHA) guidelines advocate that the optimal strategy for balancing the bleeding risks of discontinuing antiplatelet therapies is to discontinue clopidogrel or ticagrelor treatment for 5 to 7 days before surgery and to discontinue prasugrel 7 to 10 days before surgery [Wright 2011] . However, these guidelines may place patients at significant risks for ischemic or thrombotic complications while they are awaiting surgery, and it is clear that the risks and benefits need to be evaluated critically for each case [Biancari 2011] . Operative intervention in the setting of thienopyridine-induced platelet inhibition has been associated with an increased need for transfusions of blood and blood products, as well as with a significant increase in postoperative complications in some series. A recent meta-analysis of 34 studies with 22,584 patients conducted by Nijjer and colleagues has demonstrated the limitations of examining the effect of clopidogrel on major bleeding in patients who receive clopidogrel therapy up until the time of CABG [Nijjer 2011] . They observed significant increases in PRBC transfusions (by 1.1 units; 95% CI, 0.58-1.64 units; P < .0001), platelet transfusions (by 0.18 units; 95% CI, 0.14-0.21; P = .006), and fresh frozen plasma transfusions (by 0.49 units; 95% CI, 0.14-0.84; P = .006) in patients with recent exposure to clopidogrel. The rate of reoperation was also increased in the clopidogrel-exposed group, compared with patients without recent clopidogrel exposure (OR, 2.32; 95% CI, 1.76-3.06; P < .001), as was the mortality rate (OR, 1.6; 95% CI, 1.30-1.96; P < .001). The important clinical findings of this meta-analysis clearly illustrate not only the controversies surrounding the management of this patient population but also the need for an appropriate agent (such as cangrelor), protocol, and guidelines to assist in safely bridging patients to surgery, as outlined and demonstrated in this study. Withholding antiplatelet therapy is also not without risk, despite current guidelines. The risks for recurrent ischemic or thrombotic events were statistically significant in the placebo arms of previous trials of thienopyridines for ACS. Furthermore, there is growing evidence that better describes the incidence and implications of acute stent thrombosis in patients who have thienopyridine therapy discontinued abruptly. Still unclear, however, are the actual risks to patients who require surgery after ACS presentation and have thienopyridine therapy withheld. Some have suggested the risk for recurrent ischemic or thrombotic complications in this perioperative "washout" period is as high as 15% [Sambu 2011] . Although that was not true in the present small study, it is nevertheless a significant concern in a potentially vulnerable patient population awaiting surgery. Clearly, urgent revascularization in the setting of recurrent or unstable symptoms increases the perioperative risks significantly. Conversely, recurrent symptoms, particularly if they are severe, may contraindicate or require postponement of surgical revascularization and therefore may limit the benefits of timely and comprehensive intervention. Unanticipated and potentially urgent changes in patient management may account for some of the differences in outcomes Pleural effusions 4 (3.9) 9 (9.4) .122
Other 12 (11.8) 7 (7.3) .286 *Many patients reported >1 event. VT indicates ventricular tachycardia; VF, ventricular fibrillation.
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and complications observed in patients who undergo CABG during the washout period.
Although the optimal strategy for transitioning patients to surgery has not been defined, several protocols are commonly used. Anticoagulation with intravenous heparin or a low molecular weight heparin is commonly used in symptomatic patients. Unfortunately, heparin-based agents have little effect on platelet inhibition, and evidence suggests that heparin could promote platelet aggregation [Gao 2011] . Similarly, continuous treatment with heparin and to a lesser extent low molecular weight heparins might increase the risk of operative complications or challenge the intraoperative management of anticoagulation owing to the development of heparin-induced thrombocytopenia or heparin resistance [Esposito 1983; Bennett-Guerrero 2005] .
Preoperative platelet inhibition with glycoprotein IIb/ IIIa receptor antagonists, such as abciximab, eptifibatide, or tirofiban has been proposed; however, studies involving these medications in the preoperative setting have demonstrated significantly increased risks of bleeding, bleeding-related complications, and costs [Aguirre 1995; Giugliano 2009 ]. In addition, these agents have longer half-lives, and therefore the timing of discontinuation before surgery can be difficult to determine-unlike cangrelor, in which platelet reactivity returns to baseline within 1 hour. Consequently, the use of these medications is typically discouraged in patients for whom surgery is indicated.
An additional challenge in managing patients who require antiplatelet therapy is determining efficacy. It is well known that patients taking oral platelet inhibitors such as clopidogrel demonstrate variable degrees of responsiveness [Gurbel 2003 ]. Recent evidence suggests, however, that residual platelet reactivity may be a better indication of thrombotic risk than the absolute response to a treatment. A consensus review of available data has identified 3 methods capable of measuring high platelet reactivity [Bonello 2010 ]. Adenosine diphosphate (ADP)-induced light transmittance aggregometry is the standard test, but it is time-consuming to perform and is nonspecific [Michelson 2004 ]. The vasodilator-stimulated phosphoprotein phosphorylation platelet reactivity index has also been used, but it is also a laboratory-based assay. VerifyNow testing, which was used for this study, is a commonly used point-of-care platelet inhibition test. This cartridge-based rapid assay directly measures ADP-induced inhibition of adenylyl cyclase, which is influenced directly by thienopyridine activity on the P2Y12 receptor. Platelet activity is measured as PRU, with lower levels correlating with increased platelet inhibition [Malinin 2006 ]. Previous studies have demonstrated that a value >240 PRU is correlated with increased short-and long-term mortality and with major adverse cardiocerebrovascular events after PCI and ACS [Patti 2008; Price 2008; Marcucci 2009] . Nevertheless, despite the evolving literature supporting the use of platelet testing, its value as a research tool, the complications associated with inadequate platelet inhibition, and the known individual variation in the response to therapies, the current ACC/AHA guidelines are not to recommend testing routinely, pending the results of trials in progress [Wright 2011] .
Another implication of our findings is that a protocol of bridging patients with cangrelor would also be useful for patients who have undergone recent stenting and require noncardiac surgery. Although the goal of this study was to determine efficacy and safety in patients undergoing CABG, the findings suggest the lack of significant bleeding, bleeding-related, and other complications, compared with placebo. These results, combined with evidence for the normalization of platelet function before surgery, imply that such bridging might also be a reasonable approach for patients receiving a thienopyridine for coronary stents and who require elective noncardiac surgery.
Limitations
Our study has several limitations. First, although the patients were randomized to either cangrelor or placebo, other aspects of preoperative management were determined by the treating physicians; therefore, decisions regarding other anticoagulation therapy might have had a confounding effect on the outcomes. The small number of patients treated with various anticoagulation regimens was too small to determine whether any complications might subsequently predispose patients to additional risks. The fact that several patients in the placebo group still had evidence of platelet inhibition at the time of surgery suggests an incomplete washout or normalization of platelet function; therefore, the residual effects of prestudy thienopyridine therapy might have confounded the bleeding risks. In addition, although our results show a lower preoperative mortality in the cangrelor-treated group, this study was not designed to adequately evaluate the risks of limiting platelet inhibition in patients awaiting surgeryclearly a topic that needs further study. Conversely, there was a slightly increased incidence of minor preoperative bleeding in the cangrelor group, which is probably not surprising given the degree of platelet inhibition achieved in the treatment patients.
conclusIons
Bridging patients with cangrelor before CABG effectively maintains platelet inhibition without significantly increasing pre-or postoperative bleeding, thrombotic or other complications, or perioperative transfusions. Use of cangrelor appears to be a viable clinical strategy for balancing the need of sustained platelet inhibition with minimizing any undue risk of bleeding or postoperative complications in patients awaiting surgery. 
